While the numbers of circulating CD4+ and CD8+ T-lymphocytes are frequently reduced in patients during the acute and subacute phases of moderate or severe SARS-CoV-2 infections [5,12], robust and diverse antibody and T-cell responses targeting multiple structural and non-structural regions of SARS-CoV-2 are present in the majority of convalescent COVID-19 patients, regardless of disease severity [13,14,15]. The gene discussed is CD4; the disease is COVID-19.